On January 28th, Peter Rahmer, an insider at Relay Therapeutics, sold 1,354 shares of the company’s stock. The shares were sold at an average price of $8.45 each, resulting in a total transaction value of $11,441.30. After the sale, Rahmer continues to hold 276,610 shares in the company.
This transaction was publicly reported as part of regulatory requirements for insider trading disclosures.
**Why this matters**
Insider transactions can provide insights into how company executives and insiders view the firm’s prospects. While a sale does not necessarily indicate negative sentiment, investors often monitor such activities as one of many factors in their decision-making process.